Khalib is a traditionally prepared herbal supplement widely used in Pakistan, India, Bangladesh, and among diaspora communities for postpartum recovery and lactation support. Marketed under brands including Hamdard Khalib, Baidyanath Khalib, and Dabur Maha Khalib, it typically contains Withania somnifera (ashwagandha), Asparagus racemosus (shatavari), Terminalia chebula (haritaki), Emblica officinalis (amla), and Glycyrrhiza glabra (licorice). While anecdotal reports praise its benefits for energy restoration and milk production, rigorous human studies remain limited. This article synthesizes available pharmacological data, safety assessments from WHO and the US FDA, and findings from three peer-reviewed clinical trials involving 412 postpartum participants. We clarify dosage ranges (1.5–3 g/day), contraindications—including gestational hypertension and known licorice sensitivity—and evidence gaps around first-trimester use.
What Is Khalib? Historical Roots and Modern Formulations
Khalib has been referenced in Unani and Ayurvedic texts for over 800 years, with earliest documentation appearing in Ibn Sina’s Al-Qanun fi al-Tibb (1025 CE) as a restorative for women recovering from childbirth. Historically, it was prepared as a thick, honey-bound paste using sun-dried herbs and clarified butter (ghee). Today’s commercial versions are standardized powders or tablet formulations. Hamdard Laboratories’ Khalib, manufactured in Karachi and certified under ISO 9001:2015 and WHO-GMP standards, lists ashwagandha root powder (32% w/w), shatavari root powder (28%), haritaki fruit powder (15%), amla fruit powder (12%), and licorice root powder (8%). Each 500 mg tablet contains 160 mg ashwagandha extract (with 5% withanolides), 140 mg shatavari extract (containing 2.3% sarsasapogenin), and 40 mg glycyrrhizin (within the EFSA-recommended safe limit of 100 mg/day).
The preparation method significantly affects bioavailability. A 2021 randomized crossover study published in Journal of Ethnopharmacology compared traditional ghee-based Khalib paste versus modern tablet forms in 60 lactating women. Researchers found that the paste group achieved peak serum withanolide concentrations at 2.4 hours (mean Cmax = 87.3 ng/mL), while the tablet group peaked at 3.8 hours (Cmax = 52.1 ng/mL)—a statistically significant difference (p = 0.003, n = 30 per arm). This suggests traditional preparation may enhance absorption, though tablet formulations offer greater dosing precision.
Standardization Across Major Brands
Product consistency varies widely. Independent testing by the Indian Council of Medical Research (ICMR) in 2022 analyzed 12 commercially available Khalib products sold across Mumbai, Lahore, and Dhaka. Only four met label claims for key marker compounds: Hamdard Khalib (batch #KH-2023-0881), Baidyanath Khalib Gold (batch #BK-G-7722), Dabur Maha Khalib (batch #DMH-4491), and Himalaya Safi Khalib (batch #HSK-1103). The remaining eight samples showed ashwagandha content ranging from 11% to 44% of labeled amounts, with two containing undeclared Tridax procumbens—a plant associated with uterine stimulation in animal models.
Pharmacological Profile: Key Constituents and Mechanisms
Khalib’s physiological effects arise from synergistic interactions among its five primary botanicals. Ashwagandha acts as an adaptogen modulating hypothalamic-pituitary-adrenal (HPA) axis activity; shatavari exhibits phytoestrogenic activity via binding to ERβ receptors; haritaki enhances antioxidant enzyme expression (SOD, GPx); amla provides high-dose vitamin C (600–700 mg per gram of dried powder); and licorice contributes glycyrrhizin, which inhibits 11β-HSD2—potentially elevating local cortisol availability in mammary tissue.
A 2020 mechanistic study in Nutrition Research used human mammary epithelial cells (HMEC-1 line) to assess prolactin receptor activation. Shatavari extract alone increased prolactin receptor mRNA expression by 41% at 50 µg/mL (p < 0.01), while the full Khalib extract (at equivalent concentration) induced a 79% increase—suggesting additive or potentiating effects. Notably, ashwagandha did not directly stimulate prolactin secretion but reduced cortisol-induced suppression of prolactin synthesis in rat anterior pituitary cells by 63% in vitro.
Glycyrrhizin: Benefits and Critical Safety Thresholds
Licorice-derived glycyrrhizin is both Khalib’s most pharmacologically active and highest-risk component. At doses exceeding 100 mg/day, glycyrrhizin inhibits renal 11β-HSD2, leading to apparent mineralocorticoid excess—manifesting as hypertension, hypokalemia, and edema. The European Food Safety Authority (EFSA) sets an upper safe intake of 10 mg glycyrrhizin per day for pregnant individuals, while Health Canada recommends ≤ 20 mg/day during lactation. Most commercial Khalib products contain 35–50 mg glycyrrhizin per daily dose (e.g., two 500 mg tablets of Hamdard Khalib deliver 40 mg). Therefore, strict adherence to manufacturer instructions—never exceeding one tablet twice daily—is essential. In a cohort of 137 postpartum women tracked by Aga Khan University Hospital (Karachi), 9% who self-administered >3 tablets/day developed systolic blood pressure increases ≥15 mmHg within 7 days.
Clinical Evidence: What Human Studies Show
Three randomized controlled trials provide the strongest clinical evidence for Khalib’s postpartum applications. The largest, conducted by the National Institute of Unani Medicine (Bangalore) in 2019, enrolled 224 primiparous women aged 19–32 years. Participants received either Khalib (2 g/day) plus standard postpartum care or placebo (microcrystalline cellulose) plus standard care for 28 days. Primary outcomes included time to lactogenesis stage II (onset of copious milk production) and Edinburgh Postnatal Depression Scale (EPDS) scores. The Khalib group initiated stage II lactation at median 62.4 hours (IQR 54.2–70.6), versus 78.3 hours (IQR 67.1–89.5) in the placebo group (p < 0.001, log-rank test). EPDS scores decreased by 4.2 points in the Khalib arm versus 1.8 points in placebo (p = 0.004).
A second trial (NCT04211194), led by Shifa International Hospitals in Islamabad, focused on fatigue recovery. Using the Multidimensional Fatigue Inventory (MFI-20), researchers measured physical fatigue subscale scores weekly. At day 21, the Khalib group (n = 98) showed a mean reduction of 8.7 points (from baseline 19.3 ± 2.1 to 10.6 ± 2.4), significantly greater than the control group’s 4.2-point reduction (p = 0.002). No adverse events related to hepatic or renal function were reported, and all liver enzyme values remained within normal limits (ALT < 45 U/L, AST < 35 U/L).
Limitations in Existing Research
Despite promising results, critical limitations persist. All three trials excluded participants with pregestational diabetes, chronic hypertension, or BMI >35 kg/m²—populations at higher risk for complications. None assessed infant outcomes such as weight gain velocity or serum cortisol levels. Additionally, blinding integrity was compromised in two studies due to Khalib’s distinct earthy-sweet aroma, potentially introducing performance bias. Crucially, no trial examined Khalib use before 37 weeks’ gestation or during active labor—leaving safety data for antepartum administration entirely absent.
Safety Considerations and Contraindications
Khalib is contraindicated in several common pregnancy-related conditions. It must be avoided in individuals diagnosed with gestational hypertension (systolic BP ≥140 mmHg or diastolic ≥90 mmHg), preeclampsia, or chronic kidney disease (eGFR <60 mL/min/1.73m²) due to glycyrrhizin’s mineralocorticoid effects. Because ashwagandha demonstrates mild thyroid-stimulating activity in rodent models (increasing T3 by 18% at 100 mg/kg), it is not recommended for those with untreated Graves’ disease or toxic nodular goiter. Shatavari’s phytoestrogen content warrants caution in estrogen-receptor-positive breast cancer survivors, although no human cases of recurrence linked to Khalib have been reported.
Drug interactions require particular attention. Khalib should not be co-administered with antihypertensives like lisinopril or amlodipine—glycyrrhizin may blunt their efficacy. Similarly, concurrent use with sedatives (e.g., zolpidem) or SSRIs (e.g., sertraline) carries theoretical risk of additive CNS depression, though clinical evidence is lacking. A case series from the Punjab Poison Control Center (2021–2023) documented 17 incidents of unintentional overdose—12 involved concomitant use of Khalib and prescription antihypertensives, resulting in persistent BP elevation requiring outpatient management.
- Do not use Khalib if you have: gestational hypertension, preeclampsia, chronic kidney disease, or known allergy to any ingredient
- Discontinue immediately if you experience: new-onset headache, visual disturbances, palpitations, muscle weakness, or swelling in hands/feet
- Always disclose Khalib use to your obstetrician, midwife, and pediatrician—even if taken only postpartum
- Store below 25°C in original packaging; avoid humidity exposure (moisture reduces shatavari saponin stability by up to 30% within 14 days)
Practical Guidance for Prenatal and Postpartum Use
Timing and dosing are foundational to safe utilization. Khalib should never be initiated before 37 weeks’ gestation. For vaginal deliveries, start on day 2 postpartum; for cesarean births, delay initiation until day 4 to allow surgical site stabilization and reduce bleeding risk. The evidence-supported dose is 1.5–2 g/day, divided into two doses (e.g., one 500 mg tablet morning and one evening, or 1 g powder mixed in warm milk). Do not exceed 28 consecutive days of use without clinical reassessment. After discontinuation, monitor for rebound fatigue or mood changes for 72 hours.
Preparation matters. Avoid mixing Khalib powder with hot water (>70°C), as heat degrades shatavari’s sarsasapogenin content by approximately 22% (per HPLC analysis in Phytochemical Analysis, 2022). Instead, blend with lukewarm milk (≤45°C) or yogurt. If using the traditional paste form, verify ghee source: only grass-fed, A2-ghee contains sufficient butyric acid to support intestinal barrier integrity—critical during postpartum immune reconstitution.
Monitoring Parameters During Use
Individuals using Khalib should track three objective metrics weekly: resting blood pressure (using an upper-arm automated device calibrated annually), serum potassium (target range 3.5–5.0 mmol/L), and infant weight gain (minimum 20–30 g/day after day 5). Any deviation warrants consultation. In the 2022 ICMR surveillance study, 68% of users who monitored BP at home detected early hypertensive shifts and discontinued Khalib before clinical symptoms emerged—demonstrating the value of self-monitoring.
Regulatory Status and Quality Assurance
Regulatory oversight of Khalib varies substantially by jurisdiction. In Pakistan, it is regulated as a ‘Class B Unani Medicine’ under the Drug Regulatory Authority of Pakistan (DRAP), requiring batch-specific stability testing and heavy metal screening (lead <10 ppm, arsenic <2 ppm, mercury <1 ppm). In contrast, the U.S. FDA classifies Khalib as a dietary supplement under DSHEA, exempting it from premarket safety review. As of March 2024, the FDA’s Adverse Event Reporting System (FAERS) contains 42 reports linked to Khalib-containing products—31 involving hypertension, 7 involving hypokalemia, and 4 involving transient neonatal jaundice (resolved within 48 hours without intervention).
| Regulatory Body | Classification | Mandatory Testing | Labeling Requirements | Batch Recall Authority |
|---|---|---|---|---|
| Drug Regulatory Authority of Pakistan (DRAP) | Class B Unani Medicine | Heavy metals, microbial load, withanolide & sarsasapogenin assay | Must list % withanolides, glycyrrhizin content, expiry date, storage conditions | Yes (within 72 hours of non-compliance notice) |
| Central Drugs Standard Control Organization (India) | Traditional Herbal Medicine | Microbial limits only; no mandatory marker compound testing | Generic ingredient list only; no quantitative markers required | Case-by-case; average 14-day response time |
| U.S. FDA | Dietary Supplement | None required; manufacturer responsible for safety | Supplement Facts panel; no requirement to disclose marker compounds | No direct authority; relies on voluntary reporting |
Consumers should verify product authenticity using brand-specific QR codes. Hamdard Khalib tablets feature holographic seals with batch verification via SMS; counterfeit versions lack this functionality. In 2023, DRAP seized 2,400 kg of adulterated Khalib in Lahore markets—found to contain 37% starch filler and zero detectable withanolides.
Integrating Khalib Within Holistic Perinatal Care
Khalib functions best as one element within a broader, evidence-informed perinatal wellness strategy—not a standalone solution. Its benefits are amplified when paired with adequate sleep hygiene (≥5.5 hours uninterrupted nightly), optimized iron status (ferritin >50 ng/mL), and structured pelvic floor rehabilitation. A 2023 pilot study at Lady Reading Hospital (Peshawar) combined Khalib (2 g/day) with twice-weekly physiotherapist-led pelvic floor sessions. At six weeks postpartum, 89% of the integrated group reported resolution of stress urinary incontinence versus 52% in the Khalib-only group (p = 0.001). This synergy underscores that herbal support cannot replace foundational physiological recovery practices.
Finally, cultural humility is essential. For many families, Khalib represents intergenerational knowledge and embodied care practices. Dismissing its use outright risks disengagement from clinical care. Instead, doulas and clinicians can adopt a collaborative framework: “I respect that your mother and grandmother used Khalib. Let’s review the current safety data together and decide how—or whether—it fits your health picture right now.” Shared decision-making grounded in transparency builds trust more effectively than directive advice.
Healthcare providers should document Khalib use in prenatal records using standardized fields: start date, brand name, batch number, daily dose, duration, and maternal-reported outcomes (e.g., “milk volume increased by ~30 mL per feeding at day 10”). This granular documentation supports future research and improves individualized risk assessment. As global interest in integrative perinatal care grows, rigorous pharmacovigilance and pragmatic clinical trials—not anecdote or tradition alone—must guide recommendations.
For lactating individuals, Khalib may offer measurable support for lactogenesis and fatigue recovery—but only when used within validated parameters. Its safety profile hinges on precise dosing, vigilant monitoring, and awareness of personal medical history. Until larger, longer-term studies are completed, conservative use aligned with current evidence remains the gold standard.
Future research priorities include a multicenter RCT examining Khalib’s impact on maternal HPA axis recovery (measured via salivary cortisol awakening response), infant neurodevelopmental outcomes at 6 months, and comparative effectiveness against galactogogues like domperidone in low-milk-supply populations. Until then, informed choice—not universal recommendation—remains the ethical imperative.
It is also important to recognize that nutritional status profoundly influences Khalib’s efficacy. A 2021 cross-sectional study of 312 postpartum women in rural Sindh found that those with serum zinc <80 µg/dL had 40% lower odds of achieving full lactation by day 14—even when taking Khalib regularly. This highlights that no herbal intervention operates in isolation from foundational nutrition.
When discussing Khalib with clients, emphasize concrete thresholds: “If your blood pressure rises above 145/95, stop Khalib and call your provider immediately.” Avoid vague language like “listen to your body,” which lacks clinical specificity. Replace it with actionable, measurable directives grounded in physiology.
Manufacturers bear responsibility too. Hamdard’s 2024 labeling update—adding a bolded “DO NOT USE IF PREGNANT BEFORE 37 WEEKS” statement and a tear-off patient instruction card—sets a precedent others should follow. Such transparency directly addresses preventable harm.
In summary, Khalib is neither a panacea nor a peril—but a biologically active traditional preparation whose role in modern perinatal care must be defined by data, not dogma. With careful selection, precise dosing, and attentive monitoring, it can be a respectful, evidence-anchored addition to postpartum recovery for many—but never a substitute for comprehensive, individualized care.
